Tags

Type your tag names separated by a space and hit enter

Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting.
Eur J Ophthalmol. 2020 Jun 25 [Online ahead of print]EJ

Abstract

BACKGROUND

To assess long-term structural and functional outcomes of intravitreal aflibercept (Eylea®) treatment for neovascular macular degeneration (nAMD) in a real-word setting.

DESIGN AND METHODS

This was a retrospective, single-centre, non-randomized interventional cohort analysis. Data from treatment-naive patients with nAMD funded for treatment with intravitreal aflibercept in the period between 1 September 2013 and 28 February 2014 and who finished 4-year follow-up entered the analysis. Epidemiological data, visual acuity (VA) measured on ETDRS charts and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2, 3 and 4 were also recorded.

RESULTS

Ninety-four eyes of 89 patients finished 4-year follow-up. The mean number of aflibercept injections received over 4 years was 19.3. At baseline, the mean VA (SD) (Snellen) was 54.1 ± 15.5 (20/100) ETDRS letters whilst the mean CSM (SD) was 296 ± 81 µm. At 4 years, the mean VA (SD) (Snellen) was 60.4 ± 20.0 (20/63) ETDRS letters (p < 0.0001). Mean CSMT (SD) was 218 ± 79 μm (p < 0.0001). Thirty-three percent of eyes gained ⩾15 ETDRS letters at end of 4 years, and 66 (70%) eyes had no macular fluid at the end of the follow-up.

CONCLUSION AND RELEVANCE

The results suggest that good long-term morphological and functional treatment outcomes can be achieved using intravitreal aflibercept for nAMD in a real-life clinical setting.

Authors+Show Affiliations

NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.Ophthalmology Department, University Hospital Centre Split, Split, Croatia.NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32586117

Citation

Lukic, Marko, et al. "Four-year Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration: Results From Real-life Setting." European Journal of Ophthalmology, 2020, p. 1120672120938565.
Lukic M, Eleftheriadou M, Hamilton RD, et al. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. Eur J Ophthalmol. 2020.
Lukic, M., Eleftheriadou, M., Hamilton, R. D., Rajendram, R., Bucan, K., & Patel, P. J. (2020). Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. European Journal of Ophthalmology, 1120672120938565. https://doi.org/10.1177/1120672120938565
Lukic M, et al. Four-year Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration: Results From Real-life Setting. Eur J Ophthalmol. 2020 Jun 25;1120672120938565. PubMed PMID: 32586117.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. AU - Lukic,Marko, AU - Eleftheriadou,Maria, AU - Hamilton,Robin D, AU - Rajendram,Ranjan, AU - Bucan,Kajo, AU - Patel,Praveen J, Y1 - 2020/06/25/ PY - 2020/6/27/entrez KW - Age-related macular degeneration KW - genetics KW - molecular KW - pharmacology KW - retina KW - retina – medical therapies KW - retinal pathology/research SP - 1120672120938565 EP - 1120672120938565 JF - European journal of ophthalmology JO - Eur J Ophthalmol N2 - BACKGROUND: To assess long-term structural and functional outcomes of intravitreal aflibercept (Eylea®) treatment for neovascular macular degeneration (nAMD) in a real-word setting. DESIGN AND METHODS: This was a retrospective, single-centre, non-randomized interventional cohort analysis. Data from treatment-naive patients with nAMD funded for treatment with intravitreal aflibercept in the period between 1 September 2013 and 28 February 2014 and who finished 4-year follow-up entered the analysis. Epidemiological data, visual acuity (VA) measured on ETDRS charts and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2, 3 and 4 were also recorded. RESULTS: Ninety-four eyes of 89 patients finished 4-year follow-up. The mean number of aflibercept injections received over 4 years was 19.3. At baseline, the mean VA (SD) (Snellen) was 54.1 ± 15.5 (20/100) ETDRS letters whilst the mean CSM (SD) was 296 ± 81 µm. At 4 years, the mean VA (SD) (Snellen) was 60.4 ± 20.0 (20/63) ETDRS letters (p < 0.0001). Mean CSMT (SD) was 218 ± 79 μm (p < 0.0001). Thirty-three percent of eyes gained ⩾15 ETDRS letters at end of 4 years, and 66 (70%) eyes had no macular fluid at the end of the follow-up. CONCLUSION AND RELEVANCE: The results suggest that good long-term morphological and functional treatment outcomes can be achieved using intravitreal aflibercept for nAMD in a real-life clinical setting. SN - 1724-6016 UR - https://www.unboundmedicine.com/medline/citation/32586117/Four-year_outcomes_of_aflibercept_treatment_for_neovascular_age-related_macular_degeneration:_Results_from_real-life_setting L2 - https://journals.sagepub.com/doi/10.1177/1120672120938565?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.